Patient characteristics at diagnosis and at end of study
| Patient characteristics (n = 160) . | Patients who express ABL-BCR (n = 103) . | Patients who do not express ABL-BCR (n = 57) . |
|---|---|---|
| Sex (M/F) | 58/45 | 30/27 |
| Median age, y (interquartile range) | 47 (38-58) | 47 (37-57) |
| Patients with splenomegaly, no. (%)* | 33/76 (43) | 23/33 (70)† |
| Median platelet count × 109/L, no. (interquartile range)* | 382 (266-603) | 335 (213-498) |
| Median peripheral blood blasts as % of WCC (interquartile range)* | 1 (0-2) | 2 (0-3) |
| Sokal score (%) | ||
| No. patients assessed | 76 | 33 |
| High score, no. | 22 (29) | 12 (36) |
| Intermediate score, no. | 28 (37) | 12 (36) |
| Low score, no. | 26 (34) | 9 (28) |
| Hasford score (%) | ||
| No. patients assessed | 75 | 31 |
| High score, no. | 15 (20) | 9 (29) |
| Intermediate score, no. | 32 (43) | 14 (45) |
| Low score, no. | 28 (37) | 8 (26) |
| Treatment type (%) | ||
| IFN-α ± oral chemotherapy score, no. | 103 (100) | 53 (93) |
| Other chemotherapy | 35 (34) | 14 (24) |
| STI571 | 85 (82) | 44 (77) |
| BMT | ||
| Allogeneic | 15 (14) | 10 (18) |
| Autologous | 3 (3) | 1 (2) |
| Karyotype (%) | ||
| Classical Ph | 99 (96) | 51 (89) |
| Complex/variant Ph | 4 (4) | 6 (11) |
| Patients at end of study, no. (%) | ||
| Alive | 76 (74) | 38 (66) |
| Censored during study | 15 (14) | 10 (18) |
| Dead | 12 (12) | 9 (16) |
| Patient characteristics (n = 160) . | Patients who express ABL-BCR (n = 103) . | Patients who do not express ABL-BCR (n = 57) . |
|---|---|---|
| Sex (M/F) | 58/45 | 30/27 |
| Median age, y (interquartile range) | 47 (38-58) | 47 (37-57) |
| Patients with splenomegaly, no. (%)* | 33/76 (43) | 23/33 (70)† |
| Median platelet count × 109/L, no. (interquartile range)* | 382 (266-603) | 335 (213-498) |
| Median peripheral blood blasts as % of WCC (interquartile range)* | 1 (0-2) | 2 (0-3) |
| Sokal score (%) | ||
| No. patients assessed | 76 | 33 |
| High score, no. | 22 (29) | 12 (36) |
| Intermediate score, no. | 28 (37) | 12 (36) |
| Low score, no. | 26 (34) | 9 (28) |
| Hasford score (%) | ||
| No. patients assessed | 75 | 31 |
| High score, no. | 15 (20) | 9 (29) |
| Intermediate score, no. | 32 (43) | 14 (45) |
| Low score, no. | 28 (37) | 8 (26) |
| Treatment type (%) | ||
| IFN-α ± oral chemotherapy score, no. | 103 (100) | 53 (93) |
| Other chemotherapy | 35 (34) | 14 (24) |
| STI571 | 85 (82) | 44 (77) |
| BMT | ||
| Allogeneic | 15 (14) | 10 (18) |
| Autologous | 3 (3) | 1 (2) |
| Karyotype (%) | ||
| Classical Ph | 99 (96) | 51 (89) |
| Complex/variant Ph | 4 (4) | 6 (11) |
| Patients at end of study, no. (%) | ||
| Alive | 76 (74) | 38 (66) |
| Censored during study | 15 (14) | 10 (18) |
| Dead | 12 (12) | 9 (16) |
The patient age, treatment and survival data were available from 160 patients, with the length of chronic phase available from 159 patients. Information sufficient to perform Sokal and Hasford scores was available in 109 and 106 patients, respectively. Many patients received more than one type of therapy, so the sum of the patients in the treatment section is greater than 100%.
WCC indicates white cell count; IFN, interferon; BMT, bone marrow transplantation; Ph, Philadelphia chromosome.
Calculated from 76 patients who expressed ABL-BCRand 33 patients who did not.
Significant (P = .006).